Global Urinary-Incontinence Market

Urinary-Incontinence Comprehensive Study by Type (Stress Urinary Incontinence, Urge Urinary Incontinence, Overflow Incontinence, Functional Urinary Incontinence), Application (Hospitals, Homecare, Specialty Clinics, Others), Usage (Reusable, Disposal), Product Type (Absorbents (Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards), Non- Absorbents (Slings, Drainage Bags, Catheters, Stimulation Devices, Others)), Price Range (Low, Economic, Premium), Treatment Type (Medications, Devices), Gender (Men, Women) Players and Region - Global Market Outlook to 2030

Urinary-Incontinence Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Urinary-Incontinence
Urinary incontinence is the involuntary leakage of urine. It means a person urinates when they do not want to and they have no control over it. Control over the urinary sphincter is either lost or reduced. Urinary incontinence is a common problem that affects a lot of people. Urinary incontinence the loss of bladder control is a very common and often embarrassing problem as a person ages. The seriousness ranges from occasionally leaking urine when the individual coughs or sneezes to having an urge to urinate that's so sudden and powerful that the person aren't getting to a toilet in time and there is no control that an individual suffering from this has. Though it occurs more often as people grow old, enuresis isn't an inevitable result of aging.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketNorth America
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Asian Players will contribute the maximum growth to Global Urinary-Incontinence market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Eli Lilly the Company (United States), Lupin (India), Marksans Pharma (India), Zydus Cadila (India), Sun Pharmaceutical Industries Ltd (India), Torrent Pharmaceuticals Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Aurobindo Pharma (India), Apotex Inc (Canada), Ajanta Pharma (India) and Breckenridge Pharmaceutical, Inc (Berlin) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Alembic Pharmaceuticals Limited (India) and Inventia Healthcare Limited (India).

Segmentation Overview
AMA Research has segmented the market of Global Urinary-Incontinence market by Type (Stress Urinary Incontinence, Urge Urinary Incontinence, Overflow Incontinence and Functional Urinary Incontinence), Application (Hospitals, Homecare, Specialty Clinics and Others) and Region.



On the basis of geography, the market of Urinary-Incontinence has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Usage, the sub-segment i.e. Reusable will boost the Urinary-Incontinence market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Product Type, the sub-segment i.e. Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards] will boost the Urinary-Incontinence market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Price Range, the sub-segment i.e. Low will boost the Urinary-Incontinence market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Medications will boost the Urinary-Incontinence market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Gender, the sub-segment i.e. Men will boost the Urinary-Incontinence market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growth in Advances in the Treatment Rate and Presence of Refined Healthcare Infrastructure

Market Growth Drivers:
The Growing Cases of Urinary Incontinence, A Rise in the Vulnerable Aging Population, A Surge in Disposable Income and A Rise in Health Awareness

Challenges:
Unawareness of the Diseases

Restraints:
Preference over Other Therapies and Treatments

Opportunities:
Rise In Research and Development Activities and A Rise in Government Initiatives and Specialist Communities

Market Leaders and their expansionary development strategies
In February 2021, Axonics Modulation Technologies has acquired Contura, makers of a hydrogel-based injection to help treat stress urinary incontinence, for a combination of cash and stock totaling USD 200 million.
In November 2019, Renovia Inc. announced the US Food and Drug Administration’s (FDA) 510(k) clearance for its next-generation leva Pelvic Digital Therapeutic, which will be used for strengthening pelvic floor muscles and for the treatment of stress and mixed and mild to moderate urgency urinary incontinence (UI) in women.


Key Target Audience
Providers of Urinary Incontinence Products, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Stress Urinary Incontinence
  • Urge Urinary Incontinence
  • Overflow Incontinence
  • Functional Urinary Incontinence
By Application
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Usage
  • Reusable
  • Disposal

By Product Type
  • Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards]
  • Non- Absorbents [Slings, Drainage Bags, Catheters, Stimulation Devices, Others]

By Price Range
  • Low
  • Economic
  • Premium

By Treatment Type
  • Medications
  • Devices

By Gender
  • Men
  • Women

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Cases of Urinary Incontinence
      • 3.2.2. A Rise in the Vulnerable Aging Population
      • 3.2.3. A Surge in Disposable Income
      • 3.2.4. A Rise in Health Awareness
    • 3.3. Market Challenges
      • 3.3.1. Unawareness of the Diseases
    • 3.4. Market Trends
      • 3.4.1. Growth in Advances in the Treatment Rate
      • 3.4.2. Presence of Refined Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Urinary-Incontinence, by Type, Application, Usage, Product Type, Price Range, Treatment Type, Gender and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Urinary-Incontinence (Value)
      • 5.2.1. Global Urinary-Incontinence by: Type (Value)
        • 5.2.1.1. Stress Urinary Incontinence
        • 5.2.1.2. Urge Urinary Incontinence
        • 5.2.1.3. Overflow Incontinence
        • 5.2.1.4. Functional Urinary Incontinence
      • 5.2.2. Global Urinary-Incontinence by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Homecare
        • 5.2.2.3. Specialty Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Urinary-Incontinence by: Usage (Value)
        • 5.2.3.1. Reusable
        • 5.2.3.2. Disposal
      • 5.2.4. Global Urinary-Incontinence by: Type (Value)
        • 5.2.4.1. Stress Urinary Incontinence
        • 5.2.4.2. Urge Urinary Incontinence
        • 5.2.4.3. Overflow Incontinence
        • 5.2.4.4. Functional Urinary Incontinence
      • 5.2.5. Global Urinary-Incontinence by: Product Type (Value)
        • 5.2.5.1. Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards]
        • 5.2.5.2. Non- Absorbents [Slings, Drainage Bags, Catheters, Stimulation Devices, Others]
      • 5.2.6. Global Urinary-Incontinence by: Price Range (Value)
        • 5.2.6.1. Low
        • 5.2.6.2. Economic
        • 5.2.6.3. Premium
      • 5.2.7. Global Urinary-Incontinence by: Treatment Type (Value)
        • 5.2.7.1. Medications
        • 5.2.7.2. Devices
      • 5.2.8. Global Urinary-Incontinence by: Gender (Value)
        • 5.2.8.1. Men
        • 5.2.8.2. Women
      • 5.2.9. Global Urinary-Incontinence Region
        • 5.2.9.1. South America
          • 5.2.9.1.1. Brazil
          • 5.2.9.1.2. Argentina
          • 5.2.9.1.3. Rest of South America
        • 5.2.9.2. Asia Pacific
          • 5.2.9.2.1. China
          • 5.2.9.2.2. Japan
          • 5.2.9.2.3. India
          • 5.2.9.2.4. South Korea
          • 5.2.9.2.5. Taiwan
          • 5.2.9.2.6. Australia
          • 5.2.9.2.7. Rest of Asia-Pacific
        • 5.2.9.3. Europe
          • 5.2.9.3.1. Germany
          • 5.2.9.3.2. France
          • 5.2.9.3.3. Italy
          • 5.2.9.3.4. United Kingdom
          • 5.2.9.3.5. Netherlands
          • 5.2.9.3.6. Rest of Europe
        • 5.2.9.4. MEA
          • 5.2.9.4.1. Middle East
          • 5.2.9.4.2. Africa
        • 5.2.9.5. North America
          • 5.2.9.5.1. United States
          • 5.2.9.5.2. Canada
          • 5.2.9.5.3. Mexico
    • 5.3. Global Urinary-Incontinence (Price)
      • 5.3.1. Global Urinary-Incontinence by: Type (Price)
  • 6. Urinary-Incontinence: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly the Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Marksans Pharma (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Zydus Cadila (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceutical Industries Ltd (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Torrent Pharmaceuticals Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aurobindo Pharma (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apotex Inc (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ajanta Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Breckenridge Pharmaceutical, Inc (Berlin)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Urinary-Incontinence Sale, by Type, Application, Usage, Product Type, Price Range, Treatment Type, Gender and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Urinary-Incontinence (Value)
      • 7.2.1. Global Urinary-Incontinence by: Type (Value)
        • 7.2.1.1. Stress Urinary Incontinence
        • 7.2.1.2. Urge Urinary Incontinence
        • 7.2.1.3. Overflow Incontinence
        • 7.2.1.4. Functional Urinary Incontinence
      • 7.2.2. Global Urinary-Incontinence by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Homecare
        • 7.2.2.3. Specialty Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Urinary-Incontinence by: Usage (Value)
        • 7.2.3.1. Reusable
        • 7.2.3.2. Disposal
      • 7.2.4. Global Urinary-Incontinence by: Type (Value)
        • 7.2.4.1. Stress Urinary Incontinence
        • 7.2.4.2. Urge Urinary Incontinence
        • 7.2.4.3. Overflow Incontinence
        • 7.2.4.4. Functional Urinary Incontinence
      • 7.2.5. Global Urinary-Incontinence by: Product Type (Value)
        • 7.2.5.1. Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards]
        • 7.2.5.2. Non- Absorbents [Slings, Drainage Bags, Catheters, Stimulation Devices, Others]
      • 7.2.6. Global Urinary-Incontinence by: Price Range (Value)
        • 7.2.6.1. Low
        • 7.2.6.2. Economic
        • 7.2.6.3. Premium
      • 7.2.7. Global Urinary-Incontinence by: Treatment Type (Value)
        • 7.2.7.1. Medications
        • 7.2.7.2. Devices
      • 7.2.8. Global Urinary-Incontinence by: Gender (Value)
        • 7.2.8.1. Men
        • 7.2.8.2. Women
      • 7.2.9. Global Urinary-Incontinence Region
        • 7.2.9.1. South America
          • 7.2.9.1.1. Brazil
          • 7.2.9.1.2. Argentina
          • 7.2.9.1.3. Rest of South America
        • 7.2.9.2. Asia Pacific
          • 7.2.9.2.1. China
          • 7.2.9.2.2. Japan
          • 7.2.9.2.3. India
          • 7.2.9.2.4. South Korea
          • 7.2.9.2.5. Taiwan
          • 7.2.9.2.6. Australia
          • 7.2.9.2.7. Rest of Asia-Pacific
        • 7.2.9.3. Europe
          • 7.2.9.3.1. Germany
          • 7.2.9.3.2. France
          • 7.2.9.3.3. Italy
          • 7.2.9.3.4. United Kingdom
          • 7.2.9.3.5. Netherlands
          • 7.2.9.3.6. Rest of Europe
        • 7.2.9.4. MEA
          • 7.2.9.4.1. Middle East
          • 7.2.9.4.2. Africa
        • 7.2.9.5. North America
          • 7.2.9.5.1. United States
          • 7.2.9.5.2. Canada
          • 7.2.9.5.3. Mexico
    • 7.3. Global Urinary-Incontinence (Price)
      • 7.3.1. Global Urinary-Incontinence by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Urinary-Incontinence: by Type(USD Million)
  • Table 2. Urinary-Incontinence Stress Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 3. Urinary-Incontinence Urge Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 4. Urinary-Incontinence Overflow Incontinence , by Region USD Million (2018-2023)
  • Table 5. Urinary-Incontinence Functional Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 6. Urinary-Incontinence: by Application(USD Million)
  • Table 7. Urinary-Incontinence Hospitals , by Region USD Million (2018-2023)
  • Table 8. Urinary-Incontinence Homecare , by Region USD Million (2018-2023)
  • Table 9. Urinary-Incontinence Specialty Clinics , by Region USD Million (2018-2023)
  • Table 10. Urinary-Incontinence Others , by Region USD Million (2018-2023)
  • Table 11. Urinary-Incontinence: by Usage(USD Million)
  • Table 12. Urinary-Incontinence Reusable , by Region USD Million (2018-2023)
  • Table 13. Urinary-Incontinence Disposal , by Region USD Million (2018-2023)
  • Table 14. Urinary-Incontinence: by Type(USD Million)
  • Table 15. Urinary-Incontinence Stress Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 16. Urinary-Incontinence Urge Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 17. Urinary-Incontinence Overflow Incontinence , by Region USD Million (2018-2023)
  • Table 18. Urinary-Incontinence Functional Urinary Incontinence , by Region USD Million (2018-2023)
  • Table 19. Urinary-Incontinence: by Product Type(USD Million)
  • Table 20. Urinary-Incontinence Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards] , by Region USD Million (2018-2023)
  • Table 21. Urinary-Incontinence Non- Absorbents [Slings, Drainage Bags, Catheters, Stimulation Devices, Others] , by Region USD Million (2018-2023)
  • Table 22. Urinary-Incontinence: by Price Range(USD Million)
  • Table 23. Urinary-Incontinence Low , by Region USD Million (2018-2023)
  • Table 24. Urinary-Incontinence Economic , by Region USD Million (2018-2023)
  • Table 25. Urinary-Incontinence Premium , by Region USD Million (2018-2023)
  • Table 26. Urinary-Incontinence: by Treatment Type(USD Million)
  • Table 27. Urinary-Incontinence Medications , by Region USD Million (2018-2023)
  • Table 28. Urinary-Incontinence Devices , by Region USD Million (2018-2023)
  • Table 29. Urinary-Incontinence: by Gender(USD Million)
  • Table 30. Urinary-Incontinence Men , by Region USD Million (2018-2023)
  • Table 31. Urinary-Incontinence Women , by Region USD Million (2018-2023)
  • Table 32. South America Urinary-Incontinence, by Country USD Million (2018-2023)
  • Table 33. South America Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 34. South America Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 35. South America Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 36. South America Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 37. South America Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 38. South America Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 39. South America Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 40. Brazil Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 41. Brazil Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 42. Brazil Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 43. Brazil Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 44. Brazil Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 45. Brazil Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 46. Brazil Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 47. Argentina Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 48. Argentina Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 49. Argentina Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 50. Argentina Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 51. Argentina Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 52. Argentina Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 53. Argentina Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 54. Rest of South America Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 55. Rest of South America Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 56. Rest of South America Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 57. Rest of South America Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 58. Rest of South America Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 59. Rest of South America Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 60. Rest of South America Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 61. Asia Pacific Urinary-Incontinence, by Country USD Million (2018-2023)
  • Table 62. Asia Pacific Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 63. Asia Pacific Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 64. Asia Pacific Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 65. Asia Pacific Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 66. Asia Pacific Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 67. Asia Pacific Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 68. Asia Pacific Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 69. China Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 70. China Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 71. China Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 72. China Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 73. China Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 74. China Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 75. China Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 76. Japan Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 77. Japan Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 78. Japan Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 79. Japan Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 80. Japan Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 81. Japan Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 82. Japan Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 83. India Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 84. India Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 85. India Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 86. India Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 87. India Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 88. India Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 89. India Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 90. South Korea Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 91. South Korea Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 92. South Korea Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 93. South Korea Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 94. South Korea Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 95. South Korea Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 96. South Korea Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 97. Taiwan Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 98. Taiwan Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 99. Taiwan Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 100. Taiwan Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 101. Taiwan Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 102. Taiwan Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 103. Taiwan Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 104. Australia Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 105. Australia Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 106. Australia Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 107. Australia Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 108. Australia Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 109. Australia Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 110. Australia Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 111. Rest of Asia-Pacific Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 112. Rest of Asia-Pacific Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 113. Rest of Asia-Pacific Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 114. Rest of Asia-Pacific Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 115. Rest of Asia-Pacific Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 116. Rest of Asia-Pacific Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 117. Rest of Asia-Pacific Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 118. Europe Urinary-Incontinence, by Country USD Million (2018-2023)
  • Table 119. Europe Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 120. Europe Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 121. Europe Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 122. Europe Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 123. Europe Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 124. Europe Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 125. Europe Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 126. Germany Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 127. Germany Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 128. Germany Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 129. Germany Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 130. Germany Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 131. Germany Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 132. Germany Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 133. France Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 134. France Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 135. France Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 136. France Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 137. France Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 138. France Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 139. France Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 140. Italy Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 141. Italy Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 142. Italy Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 143. Italy Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 144. Italy Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 145. Italy Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 146. Italy Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 147. United Kingdom Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 148. United Kingdom Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 149. United Kingdom Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 150. United Kingdom Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 151. United Kingdom Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 152. United Kingdom Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 153. United Kingdom Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 154. Netherlands Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 155. Netherlands Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 156. Netherlands Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 157. Netherlands Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 158. Netherlands Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 159. Netherlands Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 160. Netherlands Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 161. Rest of Europe Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 162. Rest of Europe Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 163. Rest of Europe Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 164. Rest of Europe Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 165. Rest of Europe Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 166. Rest of Europe Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 167. Rest of Europe Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 168. MEA Urinary-Incontinence, by Country USD Million (2018-2023)
  • Table 169. MEA Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 170. MEA Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 171. MEA Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 172. MEA Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 173. MEA Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 174. MEA Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 175. MEA Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 176. Middle East Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 177. Middle East Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 178. Middle East Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 179. Middle East Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 180. Middle East Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 181. Middle East Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 182. Middle East Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 183. Africa Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 184. Africa Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 185. Africa Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 186. Africa Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 187. Africa Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 188. Africa Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 189. Africa Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 190. North America Urinary-Incontinence, by Country USD Million (2018-2023)
  • Table 191. North America Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 192. North America Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 193. North America Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 194. North America Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 195. North America Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 196. North America Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 197. North America Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 198. United States Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 199. United States Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 200. United States Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 201. United States Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 202. United States Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 203. United States Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 204. United States Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 205. Canada Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 206. Canada Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 207. Canada Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 208. Canada Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 209. Canada Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 210. Canada Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 211. Canada Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 212. Mexico Urinary-Incontinence, by Type USD Million (2018-2023)
  • Table 213. Mexico Urinary-Incontinence, by Application USD Million (2018-2023)
  • Table 214. Mexico Urinary-Incontinence, by Usage USD Million (2018-2023)
  • Table 215. Mexico Urinary-Incontinence, by Product Type USD Million (2018-2023)
  • Table 216. Mexico Urinary-Incontinence, by Price Range USD Million (2018-2023)
  • Table 217. Mexico Urinary-Incontinence, by Treatment Type USD Million (2018-2023)
  • Table 218. Mexico Urinary-Incontinence, by Gender USD Million (2018-2023)
  • Table 219. Urinary-Incontinence: by Type(USD/Units)
  • Table 220. Company Basic Information, Sales Area and Its Competitors
  • Table 221. Company Basic Information, Sales Area and Its Competitors
  • Table 222. Company Basic Information, Sales Area and Its Competitors
  • Table 223. Company Basic Information, Sales Area and Its Competitors
  • Table 224. Company Basic Information, Sales Area and Its Competitors
  • Table 225. Company Basic Information, Sales Area and Its Competitors
  • Table 226. Company Basic Information, Sales Area and Its Competitors
  • Table 227. Company Basic Information, Sales Area and Its Competitors
  • Table 228. Company Basic Information, Sales Area and Its Competitors
  • Table 229. Company Basic Information, Sales Area and Its Competitors
  • Table 230. Company Basic Information, Sales Area and Its Competitors
  • Table 231. Urinary-Incontinence: by Type(USD Million)
  • Table 232. Urinary-Incontinence Stress Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 233. Urinary-Incontinence Urge Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 234. Urinary-Incontinence Overflow Incontinence , by Region USD Million (2025-2030)
  • Table 235. Urinary-Incontinence Functional Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 236. Urinary-Incontinence: by Application(USD Million)
  • Table 237. Urinary-Incontinence Hospitals , by Region USD Million (2025-2030)
  • Table 238. Urinary-Incontinence Homecare , by Region USD Million (2025-2030)
  • Table 239. Urinary-Incontinence Specialty Clinics , by Region USD Million (2025-2030)
  • Table 240. Urinary-Incontinence Others , by Region USD Million (2025-2030)
  • Table 241. Urinary-Incontinence: by Usage(USD Million)
  • Table 242. Urinary-Incontinence Reusable , by Region USD Million (2025-2030)
  • Table 243. Urinary-Incontinence Disposal , by Region USD Million (2025-2030)
  • Table 244. Urinary-Incontinence: by Type(USD Million)
  • Table 245. Urinary-Incontinence Stress Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 246. Urinary-Incontinence Urge Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 247. Urinary-Incontinence Overflow Incontinence , by Region USD Million (2025-2030)
  • Table 248. Urinary-Incontinence Functional Urinary Incontinence , by Region USD Million (2025-2030)
  • Table 249. Urinary-Incontinence: by Product Type(USD Million)
  • Table 250. Urinary-Incontinence Absorbents [Underwear and Briefs, Drip Collectors, Bed Protectors, Pads and Guards] , by Region USD Million (2025-2030)
  • Table 251. Urinary-Incontinence Non- Absorbents [Slings, Drainage Bags, Catheters, Stimulation Devices, Others] , by Region USD Million (2025-2030)
  • Table 252. Urinary-Incontinence: by Price Range(USD Million)
  • Table 253. Urinary-Incontinence Low , by Region USD Million (2025-2030)
  • Table 254. Urinary-Incontinence Economic , by Region USD Million (2025-2030)
  • Table 255. Urinary-Incontinence Premium , by Region USD Million (2025-2030)
  • Table 256. Urinary-Incontinence: by Treatment Type(USD Million)
  • Table 257. Urinary-Incontinence Medications , by Region USD Million (2025-2030)
  • Table 258. Urinary-Incontinence Devices , by Region USD Million (2025-2030)
  • Table 259. Urinary-Incontinence: by Gender(USD Million)
  • Table 260. Urinary-Incontinence Men , by Region USD Million (2025-2030)
  • Table 261. Urinary-Incontinence Women , by Region USD Million (2025-2030)
  • Table 262. South America Urinary-Incontinence, by Country USD Million (2025-2030)
  • Table 263. South America Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 264. South America Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 265. South America Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 266. South America Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 267. South America Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 268. South America Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 269. South America Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 270. Brazil Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 271. Brazil Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 272. Brazil Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 273. Brazil Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 274. Brazil Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 275. Brazil Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 276. Brazil Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 277. Argentina Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 278. Argentina Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 279. Argentina Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 280. Argentina Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 281. Argentina Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 282. Argentina Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 283. Argentina Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 284. Rest of South America Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 285. Rest of South America Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 286. Rest of South America Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 287. Rest of South America Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 288. Rest of South America Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 289. Rest of South America Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 290. Rest of South America Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 291. Asia Pacific Urinary-Incontinence, by Country USD Million (2025-2030)
  • Table 292. Asia Pacific Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 293. Asia Pacific Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 294. Asia Pacific Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 295. Asia Pacific Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 296. Asia Pacific Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 297. Asia Pacific Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 298. Asia Pacific Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 299. China Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 300. China Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 301. China Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 302. China Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 303. China Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 304. China Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 305. China Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 306. Japan Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 307. Japan Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 308. Japan Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 309. Japan Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 310. Japan Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 311. Japan Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 312. Japan Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 313. India Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 314. India Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 315. India Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 316. India Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 317. India Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 318. India Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 319. India Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 320. South Korea Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 321. South Korea Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 322. South Korea Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 323. South Korea Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 324. South Korea Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 325. South Korea Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 326. South Korea Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 327. Taiwan Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 328. Taiwan Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 329. Taiwan Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 330. Taiwan Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 331. Taiwan Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 332. Taiwan Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 333. Taiwan Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 334. Australia Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 335. Australia Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 336. Australia Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 337. Australia Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 338. Australia Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 339. Australia Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 340. Australia Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 342. Rest of Asia-Pacific Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 343. Rest of Asia-Pacific Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 344. Rest of Asia-Pacific Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 345. Rest of Asia-Pacific Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 346. Rest of Asia-Pacific Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 347. Rest of Asia-Pacific Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 348. Europe Urinary-Incontinence, by Country USD Million (2025-2030)
  • Table 349. Europe Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 350. Europe Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 351. Europe Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 352. Europe Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 353. Europe Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 354. Europe Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 355. Europe Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 356. Germany Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 357. Germany Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 358. Germany Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 359. Germany Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 360. Germany Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 361. Germany Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 362. Germany Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 363. France Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 364. France Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 365. France Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 366. France Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 367. France Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 368. France Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 369. France Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 370. Italy Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 371. Italy Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 372. Italy Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 373. Italy Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 374. Italy Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 375. Italy Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 376. Italy Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 377. United Kingdom Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 378. United Kingdom Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 379. United Kingdom Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 380. United Kingdom Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 381. United Kingdom Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 382. United Kingdom Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 383. United Kingdom Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 384. Netherlands Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 385. Netherlands Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 386. Netherlands Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 387. Netherlands Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 388. Netherlands Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 389. Netherlands Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 390. Netherlands Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 391. Rest of Europe Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 392. Rest of Europe Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 393. Rest of Europe Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 394. Rest of Europe Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 395. Rest of Europe Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 396. Rest of Europe Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 397. Rest of Europe Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 398. MEA Urinary-Incontinence, by Country USD Million (2025-2030)
  • Table 399. MEA Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 400. MEA Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 401. MEA Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 402. MEA Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 403. MEA Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 404. MEA Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 405. MEA Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 406. Middle East Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 407. Middle East Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 408. Middle East Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 409. Middle East Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 410. Middle East Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 411. Middle East Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 412. Middle East Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 413. Africa Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 414. Africa Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 415. Africa Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 416. Africa Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 417. Africa Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 418. Africa Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 419. Africa Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 420. North America Urinary-Incontinence, by Country USD Million (2025-2030)
  • Table 421. North America Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 422. North America Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 423. North America Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 424. North America Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 425. North America Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 426. North America Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 427. North America Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 428. United States Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 429. United States Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 430. United States Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 431. United States Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 432. United States Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 433. United States Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 434. United States Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 435. Canada Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 436. Canada Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 437. Canada Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 438. Canada Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 439. Canada Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 440. Canada Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 441. Canada Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 442. Mexico Urinary-Incontinence, by Type USD Million (2025-2030)
  • Table 443. Mexico Urinary-Incontinence, by Application USD Million (2025-2030)
  • Table 444. Mexico Urinary-Incontinence, by Usage USD Million (2025-2030)
  • Table 445. Mexico Urinary-Incontinence, by Product Type USD Million (2025-2030)
  • Table 446. Mexico Urinary-Incontinence, by Price Range USD Million (2025-2030)
  • Table 447. Mexico Urinary-Incontinence, by Treatment Type USD Million (2025-2030)
  • Table 448. Mexico Urinary-Incontinence, by Gender USD Million (2025-2030)
  • Table 449. Urinary-Incontinence: by Type(USD/Units)
  • Table 450. Research Programs/Design for This Report
  • Table 451. Key Data Information from Secondary Sources
  • Table 452. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Urinary-Incontinence: by Type USD Million (2018-2023)
  • Figure 5. Global Urinary-Incontinence: by Application USD Million (2018-2023)
  • Figure 6. Global Urinary-Incontinence: by Usage USD Million (2018-2023)
  • Figure 7. Global Urinary-Incontinence: by Type USD Million (2018-2023)
  • Figure 8. Global Urinary-Incontinence: by Product Type USD Million (2018-2023)
  • Figure 9. Global Urinary-Incontinence: by Price Range USD Million (2018-2023)
  • Figure 10. Global Urinary-Incontinence: by Treatment Type USD Million (2018-2023)
  • Figure 11. Global Urinary-Incontinence: by Gender USD Million (2018-2023)
  • Figure 12. South America Urinary-Incontinence Share (%), by Country
  • Figure 13. Asia Pacific Urinary-Incontinence Share (%), by Country
  • Figure 14. Europe Urinary-Incontinence Share (%), by Country
  • Figure 15. MEA Urinary-Incontinence Share (%), by Country
  • Figure 16. North America Urinary-Incontinence Share (%), by Country
  • Figure 17. Global Urinary-Incontinence: by Type USD/Units (2018-2023)
  • Figure 18. Global Urinary-Incontinence share by Players 2023 (%)
  • Figure 19. Global Urinary-Incontinence share by Players (Top 3) 2023(%)
  • Figure 20. Global Urinary-Incontinence share by Players (Top 5) 2023(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Eli Lilly the Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly the Company (United States) Revenue: by Geography 2023
  • Figure 24. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 25. Lupin (India) Revenue: by Geography 2023
  • Figure 26. Marksans Pharma (India) Revenue, Net Income and Gross profit
  • Figure 27. Marksans Pharma (India) Revenue: by Geography 2023
  • Figure 28. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 29. Zydus Cadila (India) Revenue: by Geography 2023
  • Figure 30. Sun Pharmaceutical Industries Ltd (India) Revenue, Net Income and Gross profit
  • Figure 31. Sun Pharmaceutical Industries Ltd (India) Revenue: by Geography 2023
  • Figure 32. Torrent Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 33. Torrent Pharmaceuticals Ltd (India) Revenue: by Geography 2023
  • Figure 34. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 36. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 37. Aurobindo Pharma (India) Revenue: by Geography 2023
  • Figure 38. Apotex Inc (Canada) Revenue, Net Income and Gross profit
  • Figure 39. Apotex Inc (Canada) Revenue: by Geography 2023
  • Figure 40. Ajanta Pharma (India) Revenue, Net Income and Gross profit
  • Figure 41. Ajanta Pharma (India) Revenue: by Geography 2023
  • Figure 42. Breckenridge Pharmaceutical, Inc (Berlin) Revenue, Net Income and Gross profit
  • Figure 43. Breckenridge Pharmaceutical, Inc (Berlin) Revenue: by Geography 2023
  • Figure 44. Global Urinary-Incontinence: by Type USD Million (2025-2030)
  • Figure 45. Global Urinary-Incontinence: by Application USD Million (2025-2030)
  • Figure 46. Global Urinary-Incontinence: by Usage USD Million (2025-2030)
  • Figure 47. Global Urinary-Incontinence: by Type USD Million (2025-2030)
  • Figure 48. Global Urinary-Incontinence: by Product Type USD Million (2025-2030)
  • Figure 49. Global Urinary-Incontinence: by Price Range USD Million (2025-2030)
  • Figure 50. Global Urinary-Incontinence: by Treatment Type USD Million (2025-2030)
  • Figure 51. Global Urinary-Incontinence: by Gender USD Million (2025-2030)
  • Figure 52. South America Urinary-Incontinence Share (%), by Country
  • Figure 53. Asia Pacific Urinary-Incontinence Share (%), by Country
  • Figure 54. Europe Urinary-Incontinence Share (%), by Country
  • Figure 55. MEA Urinary-Incontinence Share (%), by Country
  • Figure 56. North America Urinary-Incontinence Share (%), by Country
  • Figure 57. Global Urinary-Incontinence: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Eli Lilly the Company (United States)
  • Lupin (India)
  • Marksans Pharma (India)
  • Zydus Cadila (India)
  • Sun Pharmaceutical Industries Ltd (India)
  • Torrent Pharmaceuticals Ltd (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Aurobindo Pharma (India)
  • Apotex Inc (Canada)
  • Ajanta Pharma (India)
  • Breckenridge Pharmaceutical, Inc (Berlin)
Additional players considered in the study are as follows:
Alembic Pharmaceuticals Limited (India) , Inventia Healthcare Limited (India)
Select User Access Type

Key Highlights of Report


Mar 2024 243 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Urinary-Incontinence Market Quantitative research analysis
Global Urinary-Incontinence Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Eli Lilly the Company (United States), Lupin (India), Marksans Pharma (India), Zydus Cadila (India), Sun Pharmaceutical Industries Ltd (India), Torrent Pharmaceuticals Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Aurobindo Pharma (India), Apotex Inc (Canada), Ajanta Pharma (India) and Breckenridge Pharmaceutical, Inc (Berlin) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growth in Advances in the Treatment Rate " is seen as one of major influencing trends for Urinary-Incontinence Market during projected period 2023-2030.
The Urinary-Incontinence market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Urinary-Incontinence Market Report?

Have a Query? Click Here

Other Related Reports

Learning Disability Treatment Comprehensive Study by Type (Medication, Individualized Educational Program (IEP), Occupational Therapy, Orton–Gillingham Approach, Others), Application (ADHD, Dyslexia,...
$ 3350
Weight Monitoring System Comprehensive Study by Type (Digital Weight Monitoring Device, Analog Weight Monitoring Device), Application (Residential, Commercial), Distribution Channel (Online, Offline)...
$ 3350
Letter Vitamins Comprehensive Study by Type (Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E), Application (Adult, Children), Distribution Channel (Online, Offline) Players and Region - Global ...
$ 3500
Antiha Antibody Comprehensive Study by Type (IgM, IgG, IgA, Other), Application (Therapeutic, Research, Diagnostic) Players and Region - Global Market Outlook to 2028
$ 3500
Medical Pads Comprehensive Study by Type (Woven, Non-Woven, Others), Application (Acute Wounds, Chronic Wounds), Usage (Reusable, Disposable), Form (Absorbent Pads, Non-Absorbent Pads), Material (Gel...
$ 3650
Veterinary Artificial Breeding Comprehensive Study by Type (Equipment, Reagents and Kits, Others), Application (Veterinary Hospitals & Clinics, Animal Husbandry, Others), Semen Type (Normal Semen, Se...
$ 3450